Efficacy and Safety of GP40081 Сompared to NovoMix® 30 FlexPen® in Type 2 Diabetes Mellitus Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 264 participants.

Also called NCT04226105

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 264 participants (planned count) (from the registry)
Sponsor
  • Geropharm Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04226105
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Russia (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04226105. Randomized; no masking; primary purpose treatment. Start 2020-01-20 (actual); primary completion 2020-09-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of GP40081 Сompared to NovoMix® 30 FlexPen® in Type 2 Diabetes Mellitus Patients
Condition
Diabetes Mellitus, Type 2
Condition
Diabetes Mellitus
Intervention (Drug)
GP40081
Intervention (Drug)
NovoMix 30
Lead sponsor
Geropharm (class: industry)

Record details

Record id
cardio:ct-nct04226105
Content hash
21b820952b6dc3c31b9c26cdb3a6a32cb53e2e15bbddb25533938903b0feb23c